Skip to main content
Premium Trial:

Request an Annual Quote

Caliper s Revenues Grow 22 Percent in Q3 As Pharmas Buy Into Its Microfluidic Screening Platform

NEW YORK, Nov. 5 (GenomeWeb News) - Caliper Life Sciences yesterday reported a 22-percent jump in third-quarter revenues and a shrinking loss as pharmaceutical companies adopt its microfluidic screening platform.


Revenues for the quarter ended Sept. 30 increased to $20.2 million from $16.5 million during the same period last year. Caliper said that during the last three months, Merck, Johnson & Johnson, and Taisho Pharmaceutical of Japanhad each purchased a LabChip 3,000 microfluidic screening system for the first time. In addition, Aventis and Pfizer recently bought additional systems, according to the company. 


Caliper spent $5.3 million on R&D during the quarter, down from $8.8 million a year ago.


The company's net loss was cut in half, to $5.1 million, or $.17 per share, compared to $10.1 million, or $.37 per share, during the third quarter of 2003.


As of Sept. 30, Caliper had $6.1 million in cash and cash equivalents and $43.1 million in short-term marketable securities.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.